{"@context":{"@vocab":"https://schema.org/","dcterms":"http://purl.org/dc/terms/","prov":"http://www.w3.org/ns/prov#"},"@type":"ItemList","@id":"https://api.ai-analytics.org/api/v1/entity/AZN/timeline","_source":{"data_provider":"AI Analytics","data_provider_url":"https://api.ai-analytics.org","license":"https://api.ai-analytics.org/license","usage_info":"https://api.ai-analytics.org/license","rights":"Source-specific terms apply; free or keyless access does not alter them.","generated_at":"2026-09-23T01:26:33.017Z","methodology_url":"https://api.ai-analytics.org/datasets/","primary_sources":{"sec.*":"https://www.sec.gov/edgar","fda.*":"https://api.fda.gov/","contracts":"https://api.usaspending.gov/","clinical.trials":"https://clinicaltrials.gov/","lobbying.filings":"https://lda.senate.gov/","epa.facilities":"https://echo.epa.gov/","court.dockets":"https://www.courtlistener.com/","cfpb.complaints":"https://www.consumerfinance.gov/data-research/consumer-complaints/","nih.grants":"https://api.reporter.nih.gov/","fed.enforcement":"https://www.federalreserve.gov/supervisionreg/enforcementactions.htm","nhtsa.recalls":"https://api.nhtsa.gov/recalls/"}},"entity":{"entity_id":8355,"canonical_name":"ASTRAZENECA PLC","cik":"0000901832","uei":null,"lei":null,"duns":null,"ticker":"AZN"},"window_days":180,"min_importance":0,"sources_queried":["sec.filings","sec.insider","sec.form144","sec.13dg","fda.recalls","fda.labels","contracts","clinical.trials","lobbying.filings","epa.facilities","uspto.patents","court.dockets","cfpb.complaints","nih.grants","fed.enforcement","nhtsa.recalls","doj.press","open.payments","dol.form5500","hud.housing","irs.bmf"],"importance_reference":{"fda.recall Class I":100,"clinical trial terminated":80,"securities class action":80,"antitrust suit":75,"schedule 13D":75,"patent litigation":70,"form144 large ($50M+)":75,"10-K restatement":75,"phase3 trial completed":70,"EPA significant violator":70,"phase3 trial in progress":60,"insider purchase":50,"phase2 trial":45,"8-K":35,"lobbying filing":30,"fda.label":30,"phase1 trial":30,"fda.recall Class III":25},"vertical_counts":{"sec":17,"clinical":100},"count":100,"timeline":[{"ts":"2026-09-08","kind":"sec.insider.a","reporter":"Sharma Mani","title":"See Remarks","shares":1,"price_per_share":162.6,"usd_value":163,"security_title":"Ordinary Shares","importance":15.0001626},{"ts":"2026-08-08","kind":"sec.insider.p","reporter":"Sharma Mani","title":"See Remarks","shares":20.233,"price_per_share":160.57,"usd_value":3249,"security_title":"Ordinary Shares","importance":50.00324881281},{"ts":"2026-07-08","kind":"sec.filing","form_type":"4","title":"4 — Sharma Mani — 2026-07-08","url_slug":"/sec/cik-0002122411/4/0001104659-26-081807","accession_number":"0001104659-26-081807","importance":30},{"ts":"2026-07-06","kind":"sec.insider.a","reporter":"Sharma Mani","title":"See Remarks","shares":2,"price_per_share":190.43,"usd_value":381,"security_title":"Ordinary Shares","importance":15.00038086},{"ts":"2026-07-01","kind":"sec.filing","form_type":"6-K","title":"6-K — ASTRAZENECA PLC — 2026-07-01","url_slug":"/sec/cik-0000901832/6-k/0001654954-26-006427","accession_number":"0001654954-26-006427","importance":30},{"ts":"2026-07-01","kind":"sec.filing","form_type":"6-K","title":"6-K — ASTRAZENECA PLC — 2026-07-01","url_slug":"/sec/cik-0000901832/6-k/0001654954-26-006430","accession_number":"0001654954-26-006430","importance":30},{"ts":"2026-06-29","kind":"sec.filing","form_type":"11-K","title":"11-K — ASTRAZENECA PLC — 2026-06-29","url_slug":"/sec/cik-0000901832/11-k/0001683168-26-005159","accession_number":"0001683168-26-005159","importance":30},{"ts":"2026-06-29","kind":"sec.filing","form_type":"6-K","title":"6-K — ASTRAZENECA PLC — 2026-06-29","url_slug":"/sec/cik-0000901832/6-k/0001654954-26-006239","accession_number":"0001654954-26-006239","importance":30},{"ts":"2026-06-29","kind":"sec.filing","form_type":"6-K","title":"6-K — ASTRAZENECA PLC — 2026-06-29","url_slug":"/sec/cik-0000901832/6-k/0001654954-26-006251","accession_number":"0001654954-26-006251","importance":30},{"ts":"2026-06-15","kind":"sec.filing","form_type":"6-K","title":"6-K — ASTRAZENECA PLC — 2026-06-15","url_slug":"/sec/cik-0000901832/6-k/0001654954-26-005964","accession_number":"0001654954-26-005964","importance":30},{"ts":"2026-06-08","kind":"sec.insider.a","reporter":"Sharma Mani","title":"See Remarks","shares":1,"price_per_share":179.75,"usd_value":180,"security_title":"Ordinary Shares","importance":15.00017975},{"ts":"2026-06-01","kind":"sec.filing","form_type":"6-K","title":"6-K — ASTRAZENECA PLC — 2026-06-01","url_slug":"/sec/cik-0000901832/6-k/0001654954-26-005586","accession_number":"0001654954-26-005586","importance":30},{"ts":"2026-06-01","kind":"sec.filing","form_type":"6-K","title":"6-K — ASTRAZENECA PLC — 2026-06-01","url_slug":"/sec/cik-0000901832/6-k/0001654954-26-005587","accession_number":"0001654954-26-005587","importance":30},{"ts":"2026-05-18","kind":"clinical.trial","reporter":"AstraZeneca","title":"Phase III Study Investigating Heart Failure and Cardiovascular Death With Baxdrostat in Combination With Dapagliflozin","security_title":"PHASE3","status":"RECRUITING","accession_number":"NCT06677060","excerpt":"[\"Heart Failure\"]","importance":60},{"ts":"2026-05-18","kind":"clinical.trial","reporter":"AstraZeneca","title":"A Study to Investigate Efficacy and Safety of PT027 Compared With PT007 in Symptomatic Chinese Adults With Asthma","security_title":"PHASE3","status":"RECRUITING","accession_number":"NCT06471257","excerpt":"[\"Asthma\"]","importance":60},{"ts":"2026-05-18","kind":"clinical.trial","reporter":"AstraZeneca","title":"A Global Study to Assess the Effects of Durvalumab With Oleclumab or Durvalumab With Monalizumab Following Concurrent Chemoradiation in Patients With Stage III Unresectable Non-Small Cell Lung Cancer","security_title":"PHASE3","status":"ACTIVE_NOT_RECRUITING","accession_number":"NCT05221840","excerpt":"[\"Non-Small Cell Lung Cancer\"]","importance":60},{"ts":"2026-05-18","kind":"clinical.trial","reporter":"AstraZeneca","title":"A Global Study to Assess the Effects of Durvalumab + Domvanalimab Following Concurrent Chemoradiation in Participants With Stage III Unresectable NSCLC","security_title":"PHASE3","status":"RECRUITING","accession_number":"NCT05211895","excerpt":"[\"Non-Small Cell Lung Cancer\"]","importance":60},{"ts":"2026-05-18","kind":"clinical.trial","reporter":"AstraZeneca","title":"Phase III, Open-label, Study of First-line Dato-DXd in Combination With Rilvegostomig for Advanced Non-squamous NSCLC With High PD-L1 Expression (TC ≥ 50%) and Without Actionable Genomic Alterations","security_title":"PHASE3","status":"RECRUITING","accession_number":"NCT06357533","excerpt":"[\"Non-Small Cell Lung Cancer\"]","importance":60},{"ts":"2026-05-18","kind":"clinical.trial","reporter":"AstraZeneca","title":"A Study of Novel Agents or Combinations as Perioperative Treatment in Participants With Locally Advanced Resectable Gastroesophageal Adenocarcinoma","security_title":"PHASE2","status":"RECRUITING","accession_number":"NCT07069712","excerpt":"[\"Gastroesophageal Adenocarcinoma\"]","importance":45},{"ts":"2026-05-18","kind":"clinical.trial","reporter":"AstraZeneca","title":"A Phase I/IIa Study of AZD8205 Given Alone or Combined, in Participants With Advanced/Metastatic Solid Malignancies","security_title":"PHASE1,PHASE2","status":"RECRUITING","accession_number":"NCT05123482","excerpt":"[\"Breast Cancer\",\"Biliary Tract Carcinoma\",\"Ovarian Cancer\",\"Endometrial Cancer\",\"Squamous Non-Small Cell Lung Cancer\"]","importance":45},{"ts":"2026-05-18","kind":"sec.filing","form_type":"6-K","title":"6-K — ASTRAZENECA PLC — 2026-05-18","url_slug":"/sec/cik-0000901832/6-k/0001654954-26-005038","accession_number":"0001654954-26-005038","importance":30},{"ts":"2026-05-18","kind":"sec.filing","form_type":"6-K","title":"6-K — ASTRAZENECA PLC — 2026-05-18","url_slug":"/sec/cik-0000901832/6-k/0001654954-26-005044","accession_number":"0001654954-26-005044","importance":30},{"ts":"2026-05-18","kind":"sec.filing","form_type":"6-K","title":"6-K — ASTRAZENECA PLC — 2026-05-18","url_slug":"/sec/cik-0000901832/6-k/0001654954-26-005049","accession_number":"0001654954-26-005049","importance":30},{"ts":"2026-05-18","kind":"clinical.trial","reporter":"AstraZeneca","title":"A Study to Assess the Relative Bioavailability of Different Subcutaneous Formulations ofAZD6234","security_title":"PHASE1","status":"RECRUITING","accession_number":"NCT07220954","excerpt":"[\"Healthy Participants\"]","importance":30},{"ts":"2026-05-18","kind":"clinical.trial","reporter":"AstraZeneca","title":"Acalabrutinib Monotherapy vs Investigator's Choice of Treatment in Patients With CL Leukaemia and Heart Failure","security_title":"PHASE4","status":"RECRUITING","accession_number":"NCT06651970","excerpt":"[\"Chronic Lymphocytic Leukaemia\",\"Heart Failure\"]","importance":25},{"ts":"2026-05-18","kind":"clinical.trial","reporter":"AstraZeneca","title":"Real-World Outcomes of Resected EGFR-Mutated NSCLC Patients Treated With Adjuvant EGFR-TKI in China","security_title":null,"status":"NOT_YET_RECRUITING","accession_number":"NCT07593248","excerpt":"[\"Lung Cancer\"]","importance":25},{"ts":"2026-05-15","kind":"clinical.trial","reporter":"AstraZeneca","title":"Study to Investigate Efficacy, Safety, and Tolerability of Zibotentan/Dapagliflozin Compared to Dapagliflozin in Participants With Chronic Kidney Disease and High Proteinuria (ZENITH High Proteinuria)","security_title":"PHASE3","status":"ACTIVE_NOT_RECRUITING","accession_number":"NCT06087835","excerpt":"[\"Chronic Kidney Disease With High Proteinuria\"]","importance":60},{"ts":"2026-05-15","kind":"clinical.trial","reporter":"AstraZeneca","title":"A Trial to Investigate Benralizumab in Children With Eosinophilic Diseases","security_title":"PHASE3","status":"RECRUITING","accession_number":"NCT06512883","excerpt":"[\"Eosinophilic Granulomatosis With Polyangiitis (EGPA)\",\"Hypereosinophilia Syndrome (HES)\"]","importance":60},{"ts":"2026-05-15","kind":"clinical.trial","reporter":"AstraZeneca","title":"An Open-label Study to Assess Safety and Efficacy of SZC in Paediatric Patients With Hyperkalaemia","security_title":"PHASE3","status":"RECRUITING","accession_number":"NCT03813407","excerpt":"[\"Hyperkalaemia\"]","importance":60},{"ts":"2026-05-15","kind":"clinical.trial","reporter":"AstraZeneca","title":"Phase Ib/II Platform Study of Multiple Anti-Cancer Agents in Participants With Metastatic Prostate Cancer","security_title":"PHASE1,PHASE2","status":"NOT_YET_RECRUITING","accession_number":"NCT07590934","excerpt":"[\"Metastatic Prostate Cancer\"]","importance":45},{"ts":"2026-05-15","kind":"clinical.trial","reporter":"AstraZeneca","title":"A Study to Investigate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Immunogenicity of AZD1613 in Healthy Participants.","security_title":"PHASE1","status":"RECRUITING","accession_number":"NCT06995820","excerpt":"[\"Healthy\"]","importance":30},{"ts":"2026-05-15","kind":"clinical.trial","reporter":"AstraZeneca","title":"A Study to Investigate the Effect of AZD5004 on Mitiglinide and Pioglitazone in Healthy Participants","security_title":"PHASE1","status":"ACTIVE_NOT_RECRUITING","accession_number":"NCT07444424","excerpt":"[\"Healthy Participants\"]","importance":30},{"ts":"2026-05-15","kind":"clinical.trial","reporter":"AstraZeneca","title":"The Effect of Monoallelic Variants in the ALPL Gene on the Natural Course of Hypophosphatasia in Russia","security_title":null,"status":"RECRUITING","accession_number":"NCT07390240","excerpt":"[\"Hypophosphatasia\"]","importance":25},{"ts":"2026-05-15","kind":"clinical.trial","reporter":"AstraZeneca","title":"Calquence CLL 1L Japan PMS _ Japan Post-Marketing Surveillance (PMS) Study","security_title":null,"status":"COMPLETED","accession_number":"NCT05665374","excerpt":"[\"Previously Untreated Chronic Lymphocytic Leukaemia (Including Small Lymphocytic Lymphoma)\"]","importance":25},{"ts":"2026-05-15","kind":"clinical.trial","reporter":"AstraZeneca","title":"A Non-interventional Prospective Study of Early HER2-negative High-risk Breast Cancer and BRCA1/2 Mutations Prevalence in RussiA","security_title":null,"status":"ACTIVE_NOT_RECRUITING","accession_number":"NCT05939128","excerpt":"[\"Breast Cancer\"]","importance":25},{"ts":"2026-05-15","kind":"clinical.trial","reporter":"AstraZeneca","title":"Ravulizumab Treatment Outcomes in Patients With Generalized Myasthenia Gravis","security_title":null,"status":"RECRUITING","accession_number":"NCT06909253","excerpt":"[\"Myasthenia Gravis, Generalized\"]","importance":25},{"ts":"2026-05-14","kind":"clinical.trial","reporter":"AstraZeneca","title":"A Global Phase III Study of Rilvegostomig or Pembrolizumab Monotherapy for First-Line Treatment of PD-L1-high Metastatic Non-small Cell Lung Cancer","security_title":"PHASE3","status":"RECRUITING","accession_number":"NCT06868277","excerpt":"[\"Carcinoma, Non-Small Cell Lung\"]","importance":60},{"ts":"2026-05-14","kind":"clinical.trial","reporter":"AstraZeneca","title":"Phase 3 Study of T-DXd and Rilvegostomig Versus SoC in Advanced HER2-expressing Biliary Tract Cancer","security_title":"PHASE3","status":"RECRUITING","accession_number":"NCT06467357","excerpt":"[\"Biliary Tract Cancer\"]","importance":60},{"ts":"2026-05-14","kind":"clinical.trial","reporter":"AstraZeneca","title":"A Study of AZD0486 Monotherapy or in Combination With Other Anti-Cancer Agents for Mature B-Cell Malignancies","security_title":"PHASE1,PHASE2","status":"RECRUITING","accession_number":"NCT06564038","excerpt":"[\"Chronic Lymphocytic Leukaemia\",\"Small Lymphocytic Lymphoma\",\"Mantle-cell Lymphoma\",\"Large B-cell Lymphoma\",\"B-cell Non-Hodgkin Lymphoma\"]","importance":45},{"ts":"2026-05-14","kind":"sec.filing","form_type":"6-K","title":"6-K — ASTRAZENECA PLC — 2026-05-14","url_slug":"/sec/cik-0000901832/6-k/0001654954-26-004836","accession_number":"0001654954-26-004836","importance":30},{"ts":"2026-05-14","kind":"clinical.trial","reporter":"AstraZeneca","title":"A Study of Selumetinib in Chinese Paediatric and Adult Subjects With Neurofibromatosis Type 1 (NF1) and Inoperable Plexiform Neurofibromas (PN)","security_title":"PHASE1","status":"ACTIVE_NOT_RECRUITING","accession_number":"NCT04590235","excerpt":"[\"Neurofibromatosis 1\",\"Neurofibroma Plexiform\"]","importance":30},{"ts":"2026-05-14","kind":"clinical.trial","reporter":"AstraZeneca","title":"Barriers and Facilitators of Persistence With Adjuvant Osimertinib","security_title":null,"status":"NOT_YET_RECRUITING","accession_number":"NCT07542210","excerpt":"[\"Non-small Cell Lung Cancer\"]","importance":25},{"ts":"2026-05-13","kind":"clinical.trial","reporter":"AstraZeneca","title":"A Study Evaluating the Efficacy of Budesonide, Glycopyrronium and Formoterol Fumarate Metered Dosed Inhaler on Cardiopulmonary Outcomes in Chronic Obstructive Pulmonary Disease","security_title":"PHASE3","status":"RECRUITING","accession_number":"NCT06283966","excerpt":"[\"COPD (Chronic Obstructive Pulmonary Disease)\"]","importance":60},{"ts":"2026-05-13","kind":"clinical.trial","reporter":"AstraZeneca","title":"Randomised Clinical Trial to Investigate Efficacy and Safety of Benralizumab 30 mg SC as an add-on Therapy in Uncontrolled Eosinophilic Asthma Patients Treated With Medium-dose ICS-LABA Compared to Conventional Escalation to High-dose ICS-LABA Treatment","security_title":"PHASE3","status":"RECRUITING","accession_number":"NCT06750289","excerpt":"[\"Eosinophilic Asthma\"]","importance":60},{"ts":"2026-05-13","kind":"clinical.trial","reporter":"AstraZeneca","title":"A Study of Durvalumab as Consolidation Therapy in Non-Small Cell Lung Cancer Patients","security_title":"PHASE3","status":"ACTIVE_NOT_RECRUITING","accession_number":"NCT03706690","excerpt":"[\"Carcinoma, Non-Small-Cell Lung\"]","importance":60},{"ts":"2026-05-13","kind":"clinical.trial","reporter":"AstraZeneca","title":"Study to Compare the Efficacy and Safety of Olaparib When Given in Combination With Carboplatin and Paclitaxel, Compared With Carboplatin and Paclitaxel in Patients With Advanced Ovarian Cancer","security_title":"PHASE2","status":"ACTIVE_NOT_RECRUITING","accession_number":"NCT01081951","excerpt":"[\"Ovarian Cancer\"]","importance":45},{"ts":"2026-05-13","kind":"clinical.trial","reporter":"AstraZeneca","title":"Study to Assess the Efficacy and Safety of Adjuvant Osimertinib in NSCLC With Uncommon EGFRm","security_title":"PHASE2","status":"ACTIVE_NOT_RECRUITING","accession_number":"NCT05546866","excerpt":"[\"Non-small Cell Lung Cancer\"]","importance":45},{"ts":"2026-05-13","kind":"clinical.trial","reporter":"AstraZeneca","title":"Ph1b/2 Study of the Safety and Efficacy of T-DXd Combinations in Advanced HER2-expressing Gastric Cancer (DESTINY-Gastric03)","security_title":"PHASE2","status":"RECRUITING","accession_number":"NCT04379596","excerpt":"[\"Gastric Cancer\"]","importance":45},{"ts":"2026-05-13","kind":"clinical.trial","reporter":"AstraZeneca","title":"A Phase I Study Comparing the Relative Bioavailability of a Fixed-Dose Combination of Laroprovstat/Rosuvastatin vs Their Single Therapy Products in Healthy Adults","security_title":"PHASE1","status":"ACTIVE_NOT_RECRUITING","accession_number":"NCT07316608","excerpt":"[\"Healthy Participants\"]","importance":30},{"ts":"2026-05-13","kind":"clinical.trial","reporter":"AstraZeneca","title":"Epidemiological Study of Treatment Approaches in AChR-Antibody Positive Generalized Myasthenia Gravis in Russia","security_title":null,"status":"RECRUITING","accession_number":"NCT07247279","excerpt":"[\"Rare Diseases\",\"Generalized Myasthenia Gravis (gMG)\"]","importance":25},{"ts":"2026-05-13","kind":"clinical.trial","reporter":"AstraZeneca","title":"A Multi-centre Chart Review Study of Stage I-III Non-Small Cell Lung Cancer in China","security_title":null,"status":"RECRUITING","accession_number":"NCT07316062","excerpt":"[\"Non-Small-Cell Lung\"]","importance":25},{"ts":"2026-05-13","kind":"clinical.trial","reporter":"AstraZeneca","title":"DeniLA: Comprehensive Demographics and Clinical Profile of NSCLC Patients: Analyzing Guideline-Concordant Care in First-line Treatment Patterns","security_title":null,"status":"RECRUITING","accession_number":"NCT07109154","excerpt":"[\"Lung Neoplasms\"]","importance":25},{"ts":"2026-05-13","kind":"clinical.trial","reporter":"AstraZeneca","title":"Screening Tool Artificial Intelligence-based for Predicting the Genetic Risk of BREAST Cancer","security_title":null,"status":"RECRUITING","accession_number":"NCT07070128","excerpt":"[\"Breast Neoplasms\"]","importance":25},{"ts":"2026-05-13","kind":"clinical.trial","reporter":"AstraZeneca","title":"Observational Study to Evaluate the Effect and Safety of Selumetinib in Pediatric Patients With NF1-PNs","security_title":null,"status":"ACTIVE_NOT_RECRUITING","accession_number":"NCT06175637","excerpt":"[\"Neurofibroma, Plexiform\"]","importance":25},{"ts":"2026-05-13","kind":"clinical.trial","reporter":"AstraZeneca","title":"Anifrolumab Real-world Treatment Outcomes in Systemic Lupus Erythematosus","security_title":null,"status":"RECRUITING","accession_number":"NCT06673043","excerpt":"[\"Lupus Erythematosus, Systemic\"]","importance":25},{"ts":"2026-05-12","kind":"clinical.trial","reporter":"AstraZeneca","title":"A Phase Ⅲ Study of Rilvegostomig in Combination With Fluoropyrimidine and Trastuzumab Deruxtecan as the First-line Treatment for HER2-positive Gastric Cancer","security_title":"PHASE3","status":"RECRUITING","accession_number":"NCT06764875","excerpt":"[\"HER2-positive Gastric Cancer\",\"Gastroesophageal Junction Adenocarcinoma\"]","importance":60},{"ts":"2026-05-12","kind":"clinical.trial","reporter":"AstraZeneca","title":"Phase III Open Label First Line Therapy Study of MEDI 4736 (Durvalumab) With or Without Tremelimumab Versus SOC in Non Small-Cell Lung Cancer (NSCLC)","security_title":"PHASE3","status":"ACTIVE_NOT_RECRUITING","accession_number":"NCT02453282","excerpt":"[\"Non-Small-Cell Lung Carcinoma NSCLC\"]","importance":60},{"ts":"2026-05-12","kind":"clinical.trial","reporter":"AstraZeneca","title":"A Study of Dato-DXd in Inoperable or Metastatic Hormone Receptor-positive, HER2 IHC 0 Breast Cancer","security_title":"PHASE3","status":"RECRUITING","accession_number":"NCT07205822","excerpt":"[\"Breast Cancer\"]","importance":60},{"ts":"2026-05-12","kind":"clinical.trial","reporter":"AstraZeneca","title":"A Phase III Study to Investigate the Efficacy and Safety of Baxdrostat in Combination With Dapagliflozin on CKD Progression in Participants With CKD and High Blood Pressure.","security_title":"PHASE3","status":"ACTIVE_NOT_RECRUITING","accession_number":"NCT06268873","excerpt":"[\"Chronic Kidney Disease and Hypertension\"]","importance":60},{"ts":"2026-05-12","kind":"clinical.trial","reporter":"AstraZeneca","title":"Durvalumab and Tremelimumab With Lenvatinib as First-line Treatment in Patients With Unresectable Hepatocellular Carcinoma","security_title":"PHASE2","status":"ACTIVE_NOT_RECRUITING","accession_number":"NCT07081633","excerpt":"[\"Hepatocellular Carcinoma\"]","importance":45},{"ts":"2026-05-12","kind":"clinical.trial","reporter":"AstraZeneca","title":"A Trial to Learn How Safe AZD9550 Monotherapy and Combined With AZD6234 is in People With or Without Type 2 Diabetes Who Are Living With Obesity and Overweight","security_title":"PHASE1,PHASE2","status":"RECRUITING","accession_number":"NCT06151964","excerpt":"[\"Overweight and Obesity\"]","importance":45},{"ts":"2026-05-12","kind":"clinical.trial","reporter":"AstraZeneca","title":"A Study of Novel Anti-cancer Agents in Patients With Previously Untreated NSCLC","security_title":"PHASE1","status":"ACTIVE_NOT_RECRUITING","accession_number":"NCT03819465","excerpt":"[\"Metastatic Non-Small Cell Lung Cancer (NSCLC)\"]","importance":30},{"ts":"2026-05-12","kind":"clinical.trial","reporter":"AstraZeneca","title":"A Study to Investigate the Effect of Elecoglipron on Rosuvastatin and Atorvastatin in Healthy Participants","security_title":"PHASE1","status":"RECRUITING","accession_number":"NCT07534592","excerpt":"[\"Healthy Participants\"]","importance":30},{"ts":"2026-05-12","kind":"clinical.trial","reporter":"AstraZeneca","title":"Ascending Doses of Ceralasertib in Combination With Chemotherapy and/or Novel Anti Cancer Agents","security_title":"PHASE1","status":"ACTIVE_NOT_RECRUITING","accession_number":"NCT02264678","excerpt":"[\"Adv Solid Malig - H&N SCC, ATM Pro / Def NSCLC, Gastric, Breast and Ovarian Cancer\"]","importance":30},{"ts":"2026-05-12","kind":"clinical.trial","reporter":"AstraZeneca","title":"A Phase I Study of [225Ac]-AZD2284 in Patients With Metastatic Castration-Resistant Prostate Cancer","security_title":"PHASE1","status":"RECRUITING","accession_number":"NCT06879041","excerpt":"[\"Metastatic Castration-Resistant Prostate Cancer\"]","importance":30},{"ts":"2026-05-12","kind":"clinical.trial","reporter":"AstraZeneca","title":"Study for Assessing the Prevalence of Airflow Limitation in Outpatients With History of Smoking Attending Cardiology Clinics","security_title":null,"status":"RECRUITING","accession_number":"NCT07315958","excerpt":"[\"Respiratory (Chronic Obstructive Pulmonary Disease)\"]","importance":25},{"ts":"2026-05-12","kind":"clinical.trial","reporter":"AstraZeneca","title":"A Study to Investigate the Clinical Outcome and Quality of Life in Chinese Post-operative CRSwNP Patients","security_title":null,"status":"RECRUITING","accession_number":"NCT07446738","excerpt":"[\"Chronic Rhinosinusitis With Nasal Polyps\"]","importance":25},{"ts":"2026-05-12","kind":"clinical.trial","reporter":"AstraZeneca","title":"A Prospecitve Multicenter, Observational Registry Study","security_title":null,"status":"RECRUITING","accession_number":"NCT07481526","excerpt":"[\"Chronic Kidney Disease\"]","importance":25},{"ts":"2026-05-12","kind":"clinical.trial","reporter":"AstraZeneca","title":"Prospective Registry Investigating Maternal, Infant, and Lactation Outcomes in Anifrolumab Users","security_title":"PHASE4","status":"RECRUITING","accession_number":"NCT06594068","excerpt":"[\"Systemic Lupus Erythematosus\"]","importance":25},{"ts":"2026-05-12","kind":"clinical.trial","reporter":"AstraZeneca","title":"NIS to Examine the Effectiveness and Safety of Durvalumab and Olaparib in Patients With Endometrial Cancer (DUOLife)","security_title":null,"status":"RECRUITING","accession_number":"NCT06890273","excerpt":"[\"Endometrial Cancer\"]","importance":25},{"ts":"2026-05-12","kind":"clinical.trial","reporter":"AstraZeneca","title":"To Determine the Accuracy of SCreening for Occult REnal Disease (SCORED) Questionnaire for CKD Risk Among Asian Patients","security_title":null,"status":"COMPLETED","accession_number":"NCT05866276","excerpt":"[\"Chronic Kidney Disease\"]","importance":25},{"ts":"2026-05-11","kind":"clinical.trial","reporter":"AstraZeneca","title":"Phase III Study of Rilvegostomig in Combination With Bevacizumab With or Without Tremelimumab as First-line Treatment of Hepatocellular Carcinoma","security_title":"PHASE3","status":"RECRUITING","accession_number":"NCT06921785","excerpt":"[\"Hepatocellular Carcinoma\"]","importance":60},{"ts":"2026-05-11","kind":"clinical.trial","reporter":"AstraZeneca","title":"A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of AZD0780 in Participants With Dyslipidaemia","security_title":"PHASE2,PHASE3","status":"ACTIVE_NOT_RECRUITING","accession_number":"NCT06834932","excerpt":"[\"Dyslipidaemia\"]","importance":60},{"ts":"2026-05-11","kind":"clinical.trial","reporter":"AstraZeneca","title":"A First-in-human Dose Escalation and Expansion Study to Evaluate the Safety, and Tolerability of AZD8421 Alone or in Combination in Participants With Selected Advanced or Metastatic Solid Tumors","security_title":"PHASE1,PHASE2","status":"RECRUITING","accession_number":"NCT06188520","excerpt":"[\"ER+ HER2- Advanced Breast Cancer\",\"High-grade Serous Ovarian Cancer (HGSOC)\"]","importance":45},{"ts":"2026-05-11","kind":"clinical.trial","reporter":"AstraZeneca","title":"Study of AZD4512 Monotherapy or in Combination With Anticancer Agents in Participants With Acute Lymphoblastic Leukemia","security_title":"PHASE1,PHASE2","status":"RECRUITING","accession_number":"NCT07109219","excerpt":"[\"B-cell Acute Lymphoblastic Leukemia (B-ALL)\"]","importance":45},{"ts":"2026-05-11","kind":"clinical.trial","reporter":"AstraZeneca","title":"A Study of AZD3470, a PRMT5 Inhibitor, Given as Monotherapy and in Combination in Patients With MTAP Deficient Advanced/Metastatic Solid Tumors","security_title":"PHASE1,PHASE2","status":"RECRUITING","accession_number":"NCT06130553","excerpt":"[\"Advanced Solid Tumors That Are MTAP Deficient\"]","importance":45},{"ts":"2026-05-11","kind":"clinical.trial","reporter":"AstraZeneca","title":"A Study of Novel Study Interventions and Combinations in Participants With Colorectal Cancer","security_title":"PHASE2","status":"RECRUITING","accession_number":"NCT06792695","excerpt":"[\"Metastatic Colorectal Cancer\"]","importance":45},{"ts":"2026-05-11","kind":"clinical.trial","reporter":"AstraZeneca","title":"A Study to Investigate the Effect of AZD6234, AZD9550, and a Combination of AZD9550 and AZD6234 on Pharmacokinetics of Combined Oral Contraceptive Ethinyl Estradiol/Levonorgestrel in Healthy Female Participants Living With Overweight or Obesity","security_title":"PHASE1","status":"RECRUITING","accession_number":"NCT07013643","excerpt":"[\"Healthy Participants\"]","importance":30},{"ts":"2026-05-11","kind":"clinical.trial","reporter":"AstraZeneca","title":"A Phase I Study to Investigate the Effect of Hepatic Impairment on the PK, Safety, and Tolerability of AZD2693","security_title":"PHASE1","status":"COMPLETED","accession_number":"NCT05919069","excerpt":"[\"Hepatic Impairment\"]","importance":30},{"ts":"2026-05-11","kind":"clinical.trial","reporter":"AstraZeneca","title":"Tezspire Cardiac Events PASS","security_title":null,"status":"RECRUITING","accession_number":"NCT06951867","excerpt":"[\"Cardiovascular Events\",\"MACE\"]","importance":25},{"ts":"2026-05-08","kind":"clinical.trial","reporter":"AstraZeneca","title":"A Phase III Study to Assess the Effect of AZD0780 on LDL-C in Patients With Clinical ASCVD or at Risk for a First ASCVD Event","security_title":"PHASE3","status":"ACTIVE_NOT_RECRUITING","accession_number":"NCT07000123","excerpt":"[\"Cardiovascular Disease\"]","importance":60},{"ts":"2026-05-08","kind":"clinical.trial","reporter":"AstraZeneca","title":"A Phase I/II Study of AZD4512 Monotherapy or in Combination With Anticancer Agents in Participants With Relapsed/Refractory B-cell Non-Hodgkin Lymphoma","security_title":"PHASE1,PHASE2","status":"RECRUITING","accession_number":"NCT07123454","excerpt":"[\"B-cell Non-Hodgkin Lymphoma\"]","importance":45},{"ts":"2026-05-08","kind":"clinical.trial","reporter":"AstraZeneca","title":"Study of AZD0516 as Monotherapy and in Combination in Participants With Metastatic Prostate Cancer","security_title":"PHASE1,PHASE2","status":"RECRUITING","accession_number":"NCT07181161","excerpt":"[\"Metastatic Prostate Cancer\"]","importance":45},{"ts":"2026-05-08","kind":"clinical.trial","reporter":"AstraZeneca","title":"Phase I Comparative Bioavailability Study","security_title":"PHASE1","status":"ACTIVE_NOT_RECRUITING","accession_number":"NCT00777582","excerpt":"[\"Solid Tumors\"]","importance":30},{"ts":"2026-05-08","kind":"clinical.trial","reporter":"AstraZeneca","title":"A Study to Investigate the Pharmacokinetics and Safety of Subcutaneous Rilvegostomig in Adult Participants With Advanced Solid Tumors Previously Treated With Standard of Care Therapy","security_title":"PHASE1","status":"RECRUITING","accession_number":"NCT07161414","excerpt":"[\"Advanced Solid Tumors\"]","importance":30},{"ts":"2026-05-08","kind":"clinical.trial","reporter":"AstraZeneca","title":"Hyperkalemia Quality Improvement Program (HK-QIP) Study","security_title":"NA","status":"ACTIVE_NOT_RECRUITING","accession_number":"NCT06884267","excerpt":"[\"Hyperkalemia\"]","importance":25},{"ts":"2026-05-07","kind":"clinical.trial","reporter":"AstraZeneca","title":"A Study to Investigate the Efficacy and Safety of Tezepelumab in Adult Participants With Moderate to Very Severe COPD (D5241C00006)","security_title":"PHASE3","status":"RECRUITING","accession_number":"NCT06883305","excerpt":"[\"Chronic Obstructive Pulmonary Disease (COPD)\"]","importance":60},{"ts":"2026-05-07","kind":"clinical.trial","reporter":"AstraZeneca","title":"A Study to Learn How Safe AZD6621 is, How Well it Works, and How it Moves Throughout the Body Over Time, in Adult Male Participants With Metastatic Prostate Cancer","security_title":"PHASE1,PHASE2","status":"RECRUITING","accession_number":"NCT07192614","excerpt":"[\"Prostate Cancer\"]","importance":45},{"ts":"2026-05-07","kind":"clinical.trial","reporter":"AstraZeneca","title":"A Study to Evaluate the Efficacy, Safety, and PK of AZD0292 Administered IV in Participants 12 Years of Age and Older With Bronchiectasis and Chronic Pseudomonas Aeruginosa Colonization","security_title":"PHASE2","status":"RECRUITING","accession_number":"NCT07088926","excerpt":"[\"Bronchiectasis With Pseudomonas Aeruginosa Colonization\"]","importance":45},{"ts":"2026-05-07","kind":"clinical.trial","reporter":"AstraZeneca","title":"Study to Assess the Pharmacokinetic Bioequivalence of Budesonide and Albuterol With an Alternate Propellant Compared to Current Propellant.","security_title":"PHASE1","status":"COMPLETED","accession_number":"NCT06139991","excerpt":"[\"Heathy Participants\"]","importance":30},{"ts":"2026-05-07","kind":"clinical.trial","reporter":"AstraZeneca","title":"Clinical and demOgRaphic Features of Patients With Uncontrolled Severe Asthma in Russia (CORSAR)","security_title":null,"status":"RECRUITING","accession_number":"NCT06472310","excerpt":"[\"Severe Asthma\"]","importance":25},{"ts":"2026-05-06","kind":"clinical.trial","reporter":"AstraZeneca","title":"An Efficacy and Safety Study of Intravenous Anifrolumab to Treat Systemic Lupus Erythematosus in Pediatric Participants","security_title":"PHASE3","status":"RECRUITING","accession_number":"NCT05835310","excerpt":"[\"Systemic Lupus Erythematosus\"]","importance":60},{"ts":"2026-05-06","kind":"clinical.trial","reporter":"AstraZeneca","title":"DESTINY-Endometrial01: A Phase III Study of Trastuzumab Deruxtecan Plus Rilvegostomig or Pembrolizumab as First-Line Treatment of HER2-Expressing (IHC 3+/2+), Mismatch Repair Proficient (pMMR) Endometrial Cancer","security_title":"PHASE3","status":"RECRUITING","accession_number":"NCT06989112","excerpt":"[\"Endometrial Cancer\"]","importance":60},{"ts":"2026-05-06","kind":"clinical.trial","reporter":"AstraZeneca","title":"A Multicentre, Randomised, Double-blind, Parallel Group, Placebo-controlled, Time-to-first Asthma Exacerbation Phase III Efficacy and Safety Study of Benralizumab in Paediatric Patients With Severe Eosinophilic Asthma (DOMINICA)","security_title":"PHASE3","status":"RECRUITING","accession_number":"NCT05692180","excerpt":"[\"Asthma\"]","importance":60},{"ts":"2026-05-06","kind":"clinical.trial","reporter":"AstraZeneca","title":"Phase III, Open-label Study of First-line Osimertinib With or Without Datopotamab Deruxtecan for EGFRm Locally Advanced or Metastatic Non-small Cell Lung Cancer","security_title":"PHASE3","status":"RECRUITING","accession_number":"NCT06350097","excerpt":"[\"Non-small Cell Lung Cancer\"]","importance":60},{"ts":"2026-05-06","kind":"clinical.trial","reporter":"AstraZeneca","title":"AZD0120 in Relapsed/Refractory Multiple Myeloma (DURGA-1)","security_title":"PHASE1,PHASE2","status":"RECRUITING","accession_number":"NCT05850234","excerpt":"[\"Relapsed/Refractory Multiple Myeloma\"]","importance":45},{"ts":"2026-05-06","kind":"clinical.trial","reporter":"AstraZeneca","title":"AZD0305 as Monotherapy or in Combination With Anticancer Agents in Participants With Multiple Myeloma","security_title":"PHASE1,PHASE2","status":"RECRUITING","accession_number":"NCT06106945","excerpt":"[\"Multiple Myeloma\"]","importance":45},{"ts":"2026-05-06","kind":"clinical.trial","reporter":"AstraZeneca","title":"An Observational, Prospective, Multicenter Study to Evaluate the Biologic Use and Outcomes in Chinese Asthma Patients","security_title":null,"status":"ACTIVE_NOT_RECRUITING","accession_number":"NCT06605885","excerpt":"[\"Asthma\"]","importance":25},{"ts":"2026-05-06","kind":"clinical.trial","reporter":"AstraZeneca","title":"BREZTRI REGULATORY POST MARKETING SURVEILLANCE IN KOREA","security_title":null,"status":"NOT_YET_RECRUITING","accession_number":"NCT07570394","excerpt":"[\"Chronic Obstructive Pulmonary Disease (COPD)\"]","importance":25},{"ts":"2026-05-05","kind":"clinical.trial","reporter":"AstraZeneca","title":"A Phase-3, Open-Label, Randomized Study of Dato-DXd Versus Investigator's Choice of Chemotherapy (ICC) in Participants With Inoperable or Metastatic HR-Positive, HER2-Negative Breast Cancer Who Have Been Treated With One or Two Prior Lines of Systemic Chemotherapy (TROPION-Breast01)","security_title":"PHASE3","status":"ACTIVE_NOT_RECRUITING","accession_number":"NCT05104866","excerpt":"[\"Breast Cancer\"]","importance":60}]}